Eugene Cherny, MD
Plastic and Reconstructive Surgery · Des Moines, IANPI 1376679357
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.4% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 45.6% of the total. Reporting peaked in 2019 at $1,584 and has fallen 95.0% since, to $79 in 2025.
Across 152 payments — averaging $23.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Smith+Nephew$326
- Mentor Worldwide LLC$244
- Boehringer Ingelheim$187
- Sanara Medtech Inc.$186
- Johnson & Johnson$166
- plus $802 from 13 others
What the payments were for
- Speaking & faculty fees$2327%
- Food & beverage$3,27693%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 84 | $1,598 |
| Smith+Nephew | 33 | $326 |
| Mentor Worldwide LLC | 5 | $244 |
| Boehringer Ingelheim | 2 | $187 |
| Sanara Medtech Inc. | 1 | $186 |
| Johnson & Johnson(2 entities) | 3 | $166 |
| Sientra, Inc. | 6 | $150 |
| Osiris Therapeutics Inc. | 2 | $144 |
| Organogenesis Inc. | 2 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $87 |
| AstraZeneca | 1 | $81 |
| Novo Nordisk | 3 | $52 |
| Motiva USA, LLC | 1 | $42 |
| Currax Pharmaceuticals LLC | 3 | $38 |
| Avita Medical Americas, LLC | 1 | $35 |
| Imbed Biosciences Inc. | 1 | $28 |
| Convatec Inc. | 1 | $20 |
| Nalpropion Pharmaceuticals LLC | 1 | $14 |
| Pacira Pharmaceuticals Incorporated | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,508 in reported general payments places this provider in the 85th percentile of 22 plastic and reconstructive surgery providers in Iowa.
See all plastic and reconstructive surgery providers in Iowa →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 34 | $342 |
| Ondansetron Hcl | 13 | $102 |
| Cephalexin | 21 | $80 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 12 | $76 |
Paid to pharmacies, not to this prescriber.
Other plastic and reconstructive surgery in Des Moines
- William FranksDes Moines$51
- Rehan ZahidIowa City$57K
- Kendall KeckIowa City$6K
- Takintope AkinbiyiCedar Rapids$6K
- Patrick HawkesCedar Rapids$3K
- Mark FisherIowa City$2K
- Iryna ChesnokovaIowa City$2K
- Samuel MauriceClive$2K
- Allison LorenzenIowa City$1K
- Kelly LedbetterIowa City$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.